Ligand Pharmaceuticals Incorporated
Moat Score — Ligand Pharmaceuticals Incorporated
Total Moat Score
14 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Ligand's Captisol and NITRICIL platform technologies, plus a diversified portfolio of royalty rights across 12+ commercial drugs (Kyprolis, Qarziba, Rylaze, Filspari, and others) and 75+ earlier-stage programs, represent real contractual and IP-based assets, though value depends on partners' continued commercial execution rather than Ligand's own patents alone. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 3 / 5 | Ligand's infrastructure-light royalty-aggregator model lets it manage a growing portfolio with minimal incremental overhead, demonstrated by management's statement that the 120+ asset XOMA Royalty acquisition can be absorbed with almost no added operating cost. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Existing royalty rates are fixed by contract and cannot be renegotiated upward, but Ligand's track record and balance sheet give it negotiating leverage to structure favorable terms on new royalty-funding and acquisition deals, as seen in the accretive XOMA transaction. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Royalty aggregation does not exhibit a network effect; the value of one royalty asset to Ligand does not increase as it adds unrelated partner relationships. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Once a royalty or licensing agreement is signed, partner companies are contractually locked into paying Ligand for the life of the underlying patent or product, creating very high effective switching costs from the partner's side, independent of competitive dynamics. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | Biopharma royalty aggregation is dominated by a small number of scaled players (Royalty Pharma being far larger, with XOMA Royalty now being absorbed by Ligand itself), reflecting a market structure that rewards portfolio scale and deal-sourcing reputation over having many small competitors. |